Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Neoplasms 1Metastatic Non-Squamous Non-Small Cell Lung Cancer 1Melanoma 1Lung Neoplasms 1Liposarcoma 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced or Metastatic Solid Malignancies 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Adenocarcinoma 1

Interventions

Cisplatin 33Radiotherapy 23Cetuximab 18Paclitaxel 14Docetaxel 14pembrolizumab 13Carboplatin 12Fluorouracil 10Radiotherapy, Intensity-Modulated 8Nivolumab 8Drug Therapy 7Erlotinib Hydrochloride 6Panitumumab 5dacomitinib 4Radiation 4Methotrexate 4Esophagectomy 4130-nm albumin-bound paclitaxel 4durvalumab 3ON 01910 3Leucovorin 3Gemcitabine 3Chemoradiotherapy 3vandetanib 2palbociclib 2osimertinib 2nedaplatin 2fludarabine 2cabazitaxel 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Squamous Cell × sitravatinib × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡